Fact CheckerSign in

NCT06723795Active, not recruiting

Cardiovascular Assessment and Treatment During COPD Exacerbation to Improve Diagnosis and Outcomes

Early Cardiovascular Risk Assessment of Patients With COPD During Respiratory Exacerbation for the Identification and Treatment of Cardiovascular Comorbidity

Source: ClinicalTrials.gov · Last updated 25 Aug 2026

Brief summary (registry, in English)

This is a research study involving patients hospitalized for COPD flare-ups. Patients will be assigned using a non-randomized, sequential allocation strategy (a control cohort followed by an intervention cohort) to two groups: one group will only see a pulmonologist (lung doctor), and the other group will also be seen by a cardiologist (heart doctor) during their hospital stay. Both groups will fill out a questionnaire, and the pulmonologist will review their lung disease, adjust their treatment, and recommend follow-up care. The cardiologist will also assess the second group for heart diseases (like high cholesterol, diabetes, heart disease, high blood pressure, or heart failure) and start or adjust heart treatment if needed. Both groups will be followed up by phone 1, 3, 6 and 12 months later to check for changes in treatment, new heart problems, COPD flare-ups, or death.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
150 (estimated)
First submitted
4 Dec 2024
Start date
1 Mar 2025
Primary completion date
25 Jul 2026
Lead sponsor
Tel-Aviv Sourasky Medical Center
Diseases
COPD
NCT number
NCT06723795

What you commit to

  • Study type: Interventional
  • Planned participants: 150
  • From 1 Mar 2025 to the primary completion date, 25 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Unstable concurrent disease.

Age

  • Under 18 years of age.

Other

  • Unable to provide consent.

Who the study is looking for

  • Documented COPD (based on lung function tests, symptoms and relevant treatment).
  • Aged 18-75 years.
  • Mentally competent to understand and follow medical recommendations.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Tel-Aviv Sourasky Medical Center
Coordinator of this site? Confirm its status
Tel AvivIsraelUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.